Recombinant Hepatitis B Vaccine Market Size, Share and Trends Analysis, By Type (10mcg/ml and 10mcg/0.5ml), By Application (Newborn/ Children and Adult), Forecast Period (2022-2028)

Published: Jul 2022

Recombinant hepatitis B vaccine market is expected to grow at a CAGR of 5.6% during the forecast period (2022-2028). The rising incidence of acute and chronic hepatitis B infections across the globe is driving market growth. There is an increased demand for recombinant HBV vaccines 10mcg/ml and 10 mcg/0.5 ml, which provide long-lasting protection against chronic hepatitis B infection. The Hepatitis B vaccine is a preventative vaccine for hepatitis B. It's a shot that's administered to the arm or thigh. It works by causing the body to develop virus immunity.

Browse the full report description of “Recombinant Hepatitis B Vaccine Market Size, Share and Trends Analysis, By Type (10mcg/ml and 10mcg/0.5ml), By Application (Newborn/ Children and Adult), Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/recombinant-hepatitis-b-vaccine-market

The increasing prevalence of chronic HBV infections, rising awareness about vaccination programs, and rising demand for preventive vaccines are some factors driving the global recombinant hepatitis B vaccine market. In addition, the vaccine manufacturers have been significantly focusing on the development of novel recombinant hepatitis B vaccines. North America is expected to hold a significant share in the market owing to the rising number of chronic HBV cases in the region. The Latin America recombinant hepatitis B vaccine market is driven by the rising focus on the prevention and treatment of HBV infection in the region. Further, owing to the rising incidence of HBV infections and growing awareness about vaccination programs in the region, Asia Pacific is expected to witness lucrative growth in the global recombinant hepatitis B vaccine market. 

Market Coverage

The market number available for – 2021-2028

Base year- 2021

Forecast period- 2022-2028

Segment Covered- 

o By Type

o By Application 

Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape- Merck & Co., Inc., GlaxoSmithKline plc, and Pfizer Inc., among others.

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How COVID-19 impact the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How players are addressing challenges to sustain growth?

Where is the investment opportunity?

Global Recombinant Hepatitis B Vaccine Market Report by Segment 

By Type 

  • 10mcg/ml 
  • 10mcg/0.5ml

By Application 

  • Newborn/Children 
  • Adult

Global Recombinant Hepatitis B Vaccine Market Report by Region

North America

US

Canada

Europe

UK

Germany

Italy

Spain

France

Rest of Europe 

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific 

Rest of the World

Latin America

Middle-East and Africa


To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/recombinant-hepatitis-b-vaccine-market